Heinrich Heine University Düsseldorf

MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner

Retrieved on: 
Thursday, April 11, 2024
University, Kite, Sanofi, Research, MD Anderson Cancer Center, MPM, History, Takeda Pharmaceutical Company, Heinrich Heine University Düsseldorf, Senior, Patient, Intellectual property, Internal medicine, Biotechnology, AstraZeneca, Verastem Oncology, Bluebird bio, Nursing

In addition, Dr. Neumann will join MPM BioImpact portfolio company Orna Therapeutics as Chief Medical Officer.

Key Points: 
  • In addition, Dr. Neumann will join MPM BioImpact portfolio company Orna Therapeutics as Chief Medical Officer.
  • "Frank is an innovator and distinguished leader with a demonstrated history of success in CAR-based cell therapy and clinical advancement," said Ansbert Gadicke, M.D., Managing Partner of MPM BioImpact.
  • Dr. Neumann's deep clinical experience will serve to support MPM BioImpact's investment process and the advancement of its underlying portfolio companies.
  • "I'm thrilled to join the MPM BioImpact ecosystem and contribute to its patient-focused mission," said Dr. Neumann.

Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Thursday, April 11, 2024
University, Sanofi, RNA, Research, MD Anderson Cancer Center, MPM, Takeda Pharmaceutical Company, Heinrich Heine University Düsseldorf, Therapy, Bone marrow, Partner (business rank), Senior, Patient, Internal medicine, Biotechnology, AstraZeneca, Verastem Oncology, Bluebird bio

WATERTOWN, Mass., April 11, 2024 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), today announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer. In addition, Dr. Neumann will join MPM BioImpact, which built and led the launch of Orna, as an Entrepreneur Partner.

Key Points: 
  • WATERTOWN, Mass., April 11, 2024 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), today announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer.
  • In addition, Dr. Neumann will join MPM BioImpact, which built and led the launch of Orna, as an Entrepreneur Partner.
  • "We are delighted to welcome Frank, an accomplished leader with a proven track record in CAR-based cell therapy and clinical development," said Tom Barnes, Ph.D., Chief Executive Officer of Orna Therapeutics.
  • "Orna's truly innovative approach to RNA therapeutics shows incredible promise to fundamentally change the way life-threatening diseases are treated," said Dr. Neumann.

A "Chinese New Year Flavor" Spring Festival Gala was held in Germany

Retrieved on: 
Wednesday, January 24, 2024
Student, Descendants of the Dragon, Beauty, Chinese New Year, Spring Festival, Moon, Culture, Dragon, Heinrich Heine University Düsseldorf, The Spring Festival, Flower

"The beauty was stunning, and this party with a strong Eastern charm gave me a special Chinese culture lesson," sighed German student Louis Lockhart.

Key Points: 
  • "The beauty was stunning, and this party with a strong Eastern charm gave me a special Chinese culture lesson," sighed German student Louis Lockhart.
  • At 7pm local time on January 22nd, a Spring Festival Gala with a strong Chinese New Year flavor kicked off in Munich, Germany.
  • "Where there are Chinese, there is the Spring Festival.
  • The organizer and planner of the evening party, Yan Sikuan, Chairman of the Munich Student and Scholar Association, told reporters.

EQS-News: Expertise and continuity for HHLA's Executive Board

Retrieved on: 
Wednesday, January 17, 2024
Heinrich Heine University Düsseldorf, Evonik Industries, STEAG, CFO, Port of Hamburg, Finance, HSBC Trinkaus, Real estate, Deutsche Bank, Supervisory board, Acquisition, Uppsala University, HHLA, Management

Hamburger Hafen und Logistik AG (HHLA) has appointed a new member to its Executive Board for the Finance and Real Estate divisions.

Key Points: 
  • Hamburger Hafen und Logistik AG (HHLA) has appointed a new member to its Executive Board for the Finance and Real Estate divisions.
  • With these personnel decisions, the Supervisory Board of HHLA is strengthening the company by appointing experienced managers to two Management Board positions.
  • The Supervisory Board has appointed Annette Walter to the Executive Board of HHLA.
  • She has been a member of HHLA's Executive Board since 1 October 2016.

EQS-News: Biotechnology applications for the future: These start-ups impressed the jury at the 10th anniversary of the BioRiver Boost! competition

Retrieved on: 
Wednesday, September 27, 2023
Huntington's disease, CRISPR, Neuron, Wuhan Institute of Biological Products, Therapy, Cell death, Genomics, Cancer, Research, Biomarker, RNA, Consultant, Qiagen, Plant, Botany, Heinrich Heine University Düsseldorf, Engineering, Rida al-Tubuly, Miltenyi Biotec, Synthetic biology, DSM-IV codes, Autoimmunity, Fine chemical, Pharmaceutical industry, Bookbinding, Plantman, Biotechnology, Bayer, Cologne

Biotechnology applications for the future: These start-ups impressed the jury at the 10th anniversary of the BioRiver Boost!

Key Points: 
  • Biotechnology applications for the future: These start-ups impressed the jury at the 10th anniversary of the BioRiver Boost!
  • Biotechnology applications for the future: These start-ups impressed the jury at the 10th anniversary of the BioRiver Boost!
  • competition
    Düsseldorf/Hilden, September 27, 2023: The winners of the 10th BioRiver Boost!
  • The Company develops novel CRISPR nucleases into a new class of genetics-based cancer therapies and advanced genome editing tools.

New research from The Jackson Laboratory: Insights from fully sequencing 43 human Y chromosomes

Retrieved on: 
Friday, August 25, 2023
Male, DNA, Human, National Human Genome Research Institute, Neoplasm, Y, U24, Genomics, RNA, Disorder, Clemson University, Illar Hallaste, Jackson Laboratory, Chromosome, FACMG, Heinrich Heine University Düsseldorf, Fertility, Euchromatin, JAX, Biology, Paper, Research, Health, Gene, Reference genome, Genome, Disease, Birth control, Antibiotics, Agriculture

Even as the field of human genomics forged ahead at an astonishing pace, the Y chromosome— one of the sex chromosomes—has long remained overlooked.

Key Points: 
  • Even as the field of human genomics forged ahead at an astonishing pace, the Y chromosome— one of the sex chromosomes—has long remained overlooked.
  • Taken together, these two papers provide intriguing insights into human Y chromosomes, reveal the highly variable nature of Y chromosomes across individuals, and provide an important foundation for future studies on how they may be contributing to certain disorders and diseases.
  • "Our study enables the inclusion of the full Y chromosome in all future studies when sequencing male genomes to understand health and disease."
  • The work was supported in part by a U24 grant from the National Human Genome Research Institute (#HG007497).

Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)

Retrieved on: 
Thursday, June 1, 2023
Research, Neurology, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Optical, Science, Other Science, Brainstem, L1, Attack, Glial fibrillary acidic protein, Serum, Disability, Spinal cord, RCP, Heinrich Heine University Düsseldorf, Philip Niarchos, Expanded Disability Status Scale, Prognosis, NMOSD, Brain, Medicine, Biomarker, Department of Neurology, Xuanwu hospital, Disease management, EDSS, Medical school, Journal, Journal of Neurology, Neurosurgery, and Psychiatry, Patient, Risk, Randomized controlled trial, Psychiatry, Optic nerve, Neurosurgery, Disease, Medical imaging

NMOSD is most notably associated with acute attacks, which can cause irreversible damage to the optic nerve, spinal cord, brain and brain stem.

Key Points: 
  • NMOSD is most notably associated with acute attacks, which can cause irreversible damage to the optic nerve, spinal cord, brain and brain stem.
  • Disease management goals are focused on prevention of attacks, as well as understanding and tracking biomarkers that could signal these attacks.
  • The strong link suggests that higher sNfL levels may be associated with more severe attacks and increased risk of residual disability.
  • Compared with placebo, UPLIZNA was shown to hinder biomarker elevation during attacks while reducing biomarker levels over time in the absence of attacks.

TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

Retrieved on: 
Friday, March 31, 2023
FRCP, Civil service commission, Marketing, The New England Journal of Medicine, European Medicines Agency, Multiple sclerosis, Doctor of Philosophy, TG, MS, II, Committee, EMA, RMS, MD, Patient, ARR, Medicine, Neurology, Heinrich Heine University Düsseldorf, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, European Commission, CHMP, Vaccine, Pharmaceutical industry, EU

BRIUMVI was granted approval by the U.S. Food and Drug Administration on December 28, 2022, for the treatment of RMS in adults.

Key Points: 
  • BRIUMVI was granted approval by the U.S. Food and Drug Administration on December 28, 2022, for the treatment of RMS in adults.
  • Results from the ULTIMATE I & II trials were published in August 2022 in The New England Journal of Medicine.
  • Based on the CHMP recommendation, a decision by the European Commission is expected in approximately two months.
  • If granted by the European Commission, the centralised marketing authorisation is valid in all European Union (EU) Member States, Iceland, Norway and Liechtenstein.

Leading MS/PML Experts Recommend Genetic Testing to Prevent Fatal Brain Infection

Retrieved on: 
Thursday, March 16, 2023
Database, Specialty, University, Frontiers, PML, Human polyomavirus 2, Bone marrow, Black box, DRS, Encephalitis, COVID, Lupus, Multiple sclerosis, Dimethyl fumarate, MS, Inflammatory bowel disease, CLIA, Editorial, Natalizumab, MD, Patient, Standard of care, Risk, Heinrich Heine University Düsseldorf, Progressive multifocal leukoencephalopathy, Rituximab, Genetic testing, Boxed warning, FDA, Health, JC, Gene, Rheumatoid arthritis, Disease, Pharmaceutical industry, Vaccine, Neurology

NEWPORT BEACH, Calif., March 16, 2023 /PRNewswire/ -- In an editorial in the journal Frontiers in Neurology, two leading multiple sclerosis (MS) experts are advocating for genetic testing to identify MS patients who are at higher risk of developing a devastating side effect from their medications. 

Key Points: 
  • People with MS are faced with the excruciating decision of whether they should take medications that are effective in slowing the progression of the disease, but may also trigger this potentially fatal complication, a rare brain infection called progressive multifocal leukoencephalopathy (PML).
  • The widespread use of such testing could potentially allow the physician to use alternative therapies that do not carry the same risk of PML."
  • PML is caused by the JC virus, which is very common but remains dormant in the vast majority of carriers.
  • And in 2022 alone, there were nearly 600 cases in the FDA's adverse event reporting system.

The New Germany Fund, Inc. Announces Portfolio Manager Changes

Retrieved on: 
Monday, January 30, 2023
Asset Management, Professional Services, Finance, Master of Science, War, GF, Coronavirus, DWS, Investment, NYSE, Heinrich Heine University Düsseldorf, HEC Lausanne, DWS Group, Nature, Terrorism, Sale, University, Fund, Bachelor of Science, University of Mannheim Business School, Security (finance), Bank, Economics

The New Germany Fund, Inc. (NYSE: GF) (the “Fund”) announced today that Leon Cappel will replace Valerie Schueler as the Fund’s portfolio manager effective March 1, 2023.

Key Points: 
  • The New Germany Fund, Inc. (NYSE: GF) (the “Fund”) announced today that Leon Cappel will replace Valerie Schueler as the Fund’s portfolio manager effective March 1, 2023.
  • Mr. Cappel currently serves as the Fund’s deputy portfolio manager and has been a member of the Fund’s portfolio management team since 2022.
  • In addition, effective March 1, 2023, Alexander Lippert will replace Mr. Cappel as the Fund’s deputy portfolio manager.
  • The New Germany Fund, Inc. is diversified, but primarily focuses its investments in Germany, thereby increasing its vulnerability to developments in that country.